First Racial-Ethnic Breast and Cervical Cancer Screening Data

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 3
Volume 10
Issue 3

WASHINGTON-A new analysis of data from the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) shows that among women who received their first NBCCEDP Pap test between 1991 and 1998, American Indian and Alaskan Native (AI/AN) women had the highest proportion of abnormal Pap tests, while white women had the highest rate of serious cervical lesions detected by biopsy.

WASHINGTON—A new analysis of data from the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) shows that among women who received their first NBCCEDP Pap test between 1991 and 1998, American Indian and Alaskan Native (AI/AN) women had the highest proportion of abnormal Pap tests, while white women had the highest rate of serious cervical lesions detected by biopsy.

Specifically, 4.4% of AI/AN women, 3.2% of blacks, 3.0% of whites, 2.7% of Hispanics, and 1.9% of Asian and Pacific Islanders (A/PIs) had abnormal tests. Biopsies detected serious cervical lesions in 9.9 per 1,000 Pap tests among whites, followed by Hispanics with 7.6 per 1,000, blacks at 7.1 per 1,000, AI/AN women with 6.7 per 1,000, and A/PIs at 5.4 per 1,000 Pap tests.

AI/AN women were the least likely to have ever had a Pap test prior to participating in a NBCCEDP screening. Black women were the least likely to receive follow-up care after a diagnosis of a serious cervical lesion.

NBCCEDP, which is administered by the CDC, is a federally funded program that provides breast and cervical cancer screenings to older and low-income women, and underserved women of racial and ethnic minority groups.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Related Content